CSIMarket
 


Kamada Ltd   (KMDA)
Other Ticker:  
 

Kamada Ltd 's Working Capital Ratio

KMDA's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the forth quarter 2023, Working Capital Ratio deteriorated to 3.43 below Kamada Ltd 's average Working Capital Ratio.

Within Major Pharmaceutical Preparations industry 78 other companies have achieved higher Working Capital Ratio than Kamada Ltd in forth quarter 2023. While Working Capital Ratio total ranking in the forth quarter 2023 has deteriorated compared to the prior quarter from 0 to 544.

Explain Working Capital Ratio
How much in Current Assets KMDA´s has?
What is the value of KMDA´s Current Liabilities?


KMDA Working Capital Ratio (Dec 31 2023)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Change -34.49 % -34.49 % -34.49 % -34.49 % 40.05 %
Y / Y Current Assets Change 22.27 % 22.27 % 22.27 % 22.27 % 6.89 %
Working Capital Ratio MRQ 3.43 3.43 3.43 3.43 1.84
KMDA's Total Ranking # 544 # 0 # 0 # 2900 #
Seq. Current Liabilities Change 0 % 0 % 0 % -34.49 % 0 %
Seq. Current Assets Change 0 % 0 % 0 % 22.27 % 0 %



Working Capital Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 79
Healthcare Sector # 159
Overall Market # 544


Working Capital Ratio Statistics
High Average Low
7.13 3.84 1.84
(Dec 31 2020)   (Dec 31 2022)




Financial Statements
Kamada Ltd 's Current Liabilities $ 50 Millions Visit KMDA's Balance sheet
Kamada Ltd 's Current Assets $ 170 Millions Visit KMDA's Balance sheet
Source of KMDA's Sales Visit KMDA's Sales by Geography


Cumulative Kamada Ltd 's Working Capital Ratio

KMDA's Working Capital Ratio for the trailling 12 Months

KMDA Working Capital Ratio

(Dec 31 2023)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities TTM Growth -34.49 % -34.49 % -34.49 % -34.49 % 40.05 %
Y / Y Current Assets TTM Growth 22.27 % 22.27 % 22.27 % 22.27 % 6.89 %
Working Capital Ratio TTM 3.43 2.89 2.47 2.12 1.84
Total Ranking TTM # 408 # 0 # 0 # 4930 #
Seq. Current Liabilities TTM Growth 0 % 0 % 0 % -34.49 % 0 %
Seq. Current Assets TTM Growth 0 % 0 % 0 % 22.27 % 0 %


On the trailing twelve months basis KMDA Current Assets grew by 22.27 % in IV Quarter 2023 year on year, while Current Liabilities remained unchanged to $50 millions, this led to increase in in Kamada Ltd 's Working Capital Ratio to 3.43, Working Capital Ratio remained below KMDA average.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 81 other companies have achieved higher Working Capital Ratio than Kamada Ltd . While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2023 from 0 to 408.

Explain Working Capital Ratio
How much in Current Assets KMDA´s has?
What is the value of KMDA´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 82
Healthcare Sector # 164
Within the Market # 408


trailing twelve months Working Capital Ratio Statistics
High Average Low
7.13 3.94 1.84
(Dec 31 2020)   (Dec 31 2022)




Companies with similar Working Capital Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioDec 31 2023 MRQ Current AssetsDec 31 2023 MRQ Current Liabilities
Summit Therapeutics Inc   9.30 $ 189.712  Millions$ 20.405  Millions
Ac Immune Sa  9.22 $ 125.153  Millions$ 13.576  Millions
Sol gel Technologies Ltd   9.10 $ 41.167  Millions$ 4.522  Millions
Oncolytics Biotech Inc   9.01 $ 29.241  Millions$ 3.246  Millions
Inmed Pharmaceuticals Inc   8.97 $ 11.810  Millions$ 1.316  Millions
Lipella Pharmaceuticals Inc   8.90 $ 3.429  Millions$ 0.385  Millions
Lipocine Inc   8.74 $ 22.861  Millions$ 2.614  Millions
Neurogene Inc   8.72 $ 200.348  Millions$ 22.973  Millions
Abcellera Biologics Inc   8.72 $ 871.985  Millions$ 100.055  Millions
Xoma Corporation  8.68 $ 169.313  Millions$ 19.499  Millions
Artelo Biosciences Inc   8.51 $ 10.980  Millions$ 1.291  Millions
Capricor Therapeutics inc   8.14 $ 50.855  Millions$ 6.250  Millions
Bicycle Therapeutics Plc  8.08 $ 561.868  Millions$ 69.537  Millions
Centessa Pharmaceuticals Plc  8.00 $ 315.092  Millions$ 39.385  Millions
Alpine Immune Sciences Inc   7.86 $ 330.034  Millions$ 41.980  Millions
Ngm Biopharmaceuticals Inc   7.79 $ 156.444  Millions$ 20.081  Millions
Avidity Biosciences Inc   7.58 $ 611.307  Millions$ 80.680  Millions
Zymeworks Inc   7.41 $ 412.926  Millions$ 55.763  Millions
Xencor Inc  7.36 $ 623.160  Millions$ 84.709  Millions
Salarius Pharmaceuticals inc   7.30 $ 6.520  Millions$ 0.892  Millions
Kronos Bio Inc   7.24 $ 178.778  Millions$ 24.695  Millions
Siga Technologies Inc  7.17 $ 238.991  Millions$ 33.329  Millions
Zentalis Pharmaceuticals Inc   7.16 $ 496.718  Millions$ 69.367  Millions
Werewolf Therapeutics Inc   7.14 $ 138.370  Millions$ 19.378  Millions
Arcutis Biotherapeutics Inc   7.08 $ 330.431  Millions$ 46.668  Millions
Harmony Biosciences Holdings inc   7.02 $ 451.070  Millions$ 64.287  Millions
Generation Bio Co   6.83 $ 272.618  Millions$ 39.914  Millions
Anebulo Pharmaceuticals Inc   6.73 $ 6.816  Millions$ 1.014  Millions
Incannex Healthcare Inc   6.70 $ 21.332  Millions$ 3.186  Millions
Ocular Therapeutix Inc   6.66 $ 232.235  Millions$ 34.896  Millions

Date modified: 2024-03-08T06:20:17+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com